Alpha 2 delta (α2δ) ligands, gabapentin and pregabalin: What is the evidence for potential use of these ligands in irritable bowel syndrome

Jeremy D. Gale, Lesley A. Houghton

Research output: Contribution to journalArticle

36 Scopus citations

Abstract

Irritable bowel syndrome (IBS) is a complex disorder that is characterized by abdominal pain and altered bowel habit, and often associates with other gastrointestinal symptoms such as feelings of incomplete bowel movement and abdominal bloating, and extra-intestinal symptoms such as headache, dyspareunia, heartburn, muscle pain, and back pain. It also frequently coexists with conditions that may also involve central sensitization processes, such as fibromyalgia, irritable bladder disorder, and chronic cough. This review examines the evidence to date on gabapentin and pregabalin which may support further and con- tinued research and development of the α2δ ligands in disorders characterized by visceral hypersensitivity, such as IBS. The distribution of the α2δ subunit of the voltage-gated cal- cium channel, possible mechanisms of action, pre-clinical data which supports an effect on motor-sensory mechanisms and clinical evidence that points to potential benefits in patients with IBS will be discussed.

Original languageEnglish (US)
Article numberArticle 28
JournalFrontiers in Pharmacology
VolumeJUN
DOIs
StatePublished - Dec 1 2011

Keywords

  • Central sensitization
  • Gabapentin
  • Irritable bowel syndrome
  • Motility
  • Peripheral sensitization
  • Pregabalin
  • Visceral sensitivity
  • αδ ligands

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Alpha 2 delta (α<sub>2</sub>δ) ligands, gabapentin and pregabalin: What is the evidence for potential use of these ligands in irritable bowel syndrome'. Together they form a unique fingerprint.

  • Cite this